Quick Summary

Guaco (Mikania glomerata) is a plant traditionally used for respiratory conditions and as an adjuvant symptomatic herbal medicine, particularly in Brazil and other Pan American regions. Research evidence is limited and mostly preclinical or observational, with some positive preliminary findings regarding respiratory symptom management and potential antibiofilm effects in vitro.

What is It?

Guaco is a vine native to the tropical regions of South America, especially Brazil. It belongs to the Asteraceae family and has been incorporated in local traditional medicine for its respiratory benefits. The plant is typically prepared as teas, extracts, or syrups that are used to soothe respiratory symptoms.

Traditional Uses

  • Support for respiratory conditions such as coughs, colds, and bronchitis
  • Adjuvant relief of mild flu symptoms
  • Symptomatic management of upper respiratory tract ailments

Active Compounds

Guaco contains a variety of bioactive constituents that may include coumarins, flavonoids, and volatile oils. These compounds are thought to contribute to its traditional use in respiratory symptom relief and antimicrobial properties, although detailed phytochemical profiles require further elucidation.

Potential Benefits with Evidence Levels

Side Effects

No well-documented adverse effects have been reported in the clinical literature or systematic reviews reviewed. However, specific data from randomized clinical trials on adverse effects are lacking, so caution is advised.

Drug Interactions

There is no direct evidence or clinical data regarding drug interactions with Mikania glomerata. Due to the absence of comprehensive interaction studies, healthcare providers and users should exercise caution when combining this herb with other medications.

Who Should Avoid It

  • Pregnant and breastfeeding women should avoid use due to a lack of safety data.
  • Individuals with known hypersensitivity to related plants may wish to exercise caution.
  • People taking other medications should consult a healthcare professional before use given unknown interaction profiles.

Evidence Limitations

  • Most evidence comes from in vitro studies or traditional use with limited clinical trial data available.
  • No high-quality randomized controlled trials evaluating efficacy or safety of Mikania glomerata were identified.
  • No meta-analyses or systematic reviews specific to clinical outcomes with this herb have been found.
  • Safety data from phase I clinical trials are sparse and lack detailed published results.
  • Data on adverse effects, drug interactions, and special populations like pregnant or breastfeeding women are insufficient.

References

  • Silveira D et al. (2020). COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy? Front Pharmacol. PMID: 33071794
  • Diouchi J, Touré B, Ghoul S. (2024). Antibiofilm efficacy of plant extracts as root canal irrigants in endodontics: a systematic literature review. Front Dent Med. PMID: 39917707
  • Lopes LC et al. (2014). Brazilian medicinal plants to treat upper respiratory tract and bronchial illness: systematic review and meta-analyses-study protocol. BMJ Open. PMID: 25056973
  • Upton R et al. (2024). A U.S. Pharmacopeia (USP) overview of Pan American botanicals used in dietary supplements and herbal medicines. Front Pharmacol. PMID: 39281273

Last Reviewed

June 2024

Disclaimer: This information is provided for educational purposes only and is not intended as medical advice. Always consult a healthcare professional before starting any herbal regimen, especially if you have underlying conditions, are pregnant or breastfeeding, or are taking other medications.